Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells

Drug Chem Toxicol. 2010 Jul;33(3):325-8. doi: 10.3109/01480540903449715.

Abstract

Despite the important role of pyrazinamide in tuberculosis treatment, little is known about the mechanism of pyrazinamide-induced hepatotoxicity. We inhibited xanthine oxidase in HepG2 cells by using a nontoxic concentration of allopurinol, a well-known xanthine-oxidase inhibitor. This increased in vitro pyrazinamide toxicity in HepG2 cells, which suggests that the hydroxy metabolites of pyrazinamide are probably not fully responsible for pyrazinamide-induced toxicity, and that pyrazinoic acid and pyrazinamide are involved in pyrazinamide toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allopurinol / pharmacology*
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / therapeutic use*
  • Area Under Curve
  • Cell Survival / drug effects
  • Chemical and Drug Induced Liver Injury / enzymology
  • Chemical and Drug Induced Liver Injury / etiology*
  • Chemical and Drug Induced Liver Injury / metabolism
  • Drug Synergism
  • Enzyme Inhibitors / pharmacology*
  • Hep G2 Cells
  • Humans
  • Pyrazinamide / toxicity*
  • Statistics, Nonparametric
  • Xanthine Oxidase / antagonists & inhibitors*
  • Xanthine Oxidase / metabolism

Substances

  • Antitubercular Agents
  • Enzyme Inhibitors
  • Pyrazinamide
  • Allopurinol
  • Xanthine Oxidase